Cleveland – September 22, 2026 -- Inglewood Associates and Gordon Brothers confirmed that the court-appointed Receiver overseeing the sale of 925 Euclid Avenue in Cleveland has not selected a stalking horse bidder, despite months of marketing the 1.45 million-square-foot historic tower.
Hangzhou, China – September 21, 2026 -- A joint survey by asmag.com and Hikvision found that 38.2% of video security professionals call storage cost or capacity a "major challenge," while another 43.2% rate it "moderate," together accounting for 81.4% of respondents.
Asked how the storage challenge has changed compared with a year earlier, 43.2% of respondents said pressure has "increased moderately," pointing to persistent upward cost trends across video security deployments rather than a one-time spike.
Hong Kong – September 21, 2026 -- Noah Holdings Limited (NYSE: NOAH; HKEX: 6686) hosted its 2026 Global Investor Summit in Hong Kong, gathering investment professionals from Global Infrastructure Partners (a part of BlackRock), Macquarie Asset Management, Bridgepoint, HarbourVest Partners and Sumitomo Mitsui Trust Asset Management to discuss AI-driven shifts in global asset allocation for Chinese high-net-worth families.
The summit, themed "The Year of Realization: A New Chapter in Global Allocation," was organized jointly with Noah's global asset allocation platform, Olive Asset Management. Noah said its ongoing investments in funds worldwide have built long-term relationships with managers and accumulated underlying research data, which the company now combines with AI tools to validate investment judgments for client portfolios.
Jinan – September 21, 2026 -- Bestzyme, a synthetic biology unit of GenScript Biotech, has completed what it calls the world's first dedicated, automated smart production line for sweet proteins at its Jinan facility, integrating R&D, mass production and application for the ingredient category for the first time globally.
The 5,000-square-meter plant runs a fully automated fermentation-purification-freeze-drying process for Bestzyme's flagship Mellia® Brazzein sweet protein. Once operational, the line will produce over 100 tons annually, a volume the company says matches the sweetness output of 300,000 tons of sucrose. Bestzyme expects capacity to potentially double within two years.
Dallas – September 21, 2026 -- AI Hospitality Group (AIHG) launched with $7.5 million in seed funding and a pledge to deliver more than 500 basis points of gross operating profit margin improvement to hotel owners through a fully AI-native management model. The company, founded by former Remington Hospitality CEO Sloan Dean, signs hotel management agreements directly with owners and takes responsibility for the P&L rather than licensing software to existing operators.
AIHG says U.S. hotel EBITDA margins have fallen approximately 20% since 2019, while CMBS delinquency rates for limited-service hotels hit 8.35% in July 2025, more than double their 2022 low. The company cites 65% of North American hotels reporting staffing shortages in 2025, with labor costs rising 11.2% year over year.
Fountain Valley, Calif. – September 21, 2026 -- Hyundai has renewed and extended its sponsorship of the Atlanta Braves through the 2029 season, continuing a partnership that began in 2014 and has spanned the franchise's entire tenure at Truist Park and The Battery Atlanta.
The renewed deal keeps Hyundai visible through outfield wall placements in Left Field and seating bowl signage behind the Visitors Dugout, seen by fans during TV broadcasts and in-stadium attendance. Hyundai remains the presenting sponsor of the Braves Radio Network's Sunday broadcasts, which reach 170 markets across eight states, described as the largest radio network in professional sports, as well as BravesVision, the team's owned television network.
Milan – September 21, 2026 -- Tethis S.p.A. has completed the acquisition of the See.d software and engineering business unit from MACS S.r.l., gaining full control over intellectual property and engineering know-how behind its liquid biopsy platform. Alongside the transfer, Tethis signed a long-term manufacturing and supply agreement with Everex S.r.l., an Italian in-vitro diagnostic instrumentation maker, to handle production and future scale-up of the system.
See.d is the cornerstone of Tethis' liquid biopsy workflow, developed jointly with MACS to standardize pre-analytical blood processing. From a single blood sample, the platform generates plasma for cfDNA analysis and cytology slides preserving nucleated cells for downstream characterization, automating plasma separation, red blood cell lysis, and deposition onto Tethis' proprietary SmartBioSurface slides.
Iselin, N.J. – September 21, 2026 -- Hackensack Meridian Health's Board of Trustees announced that CEO Robert C. Garrett will retire effective June 30, 2027, ending a tenure that built New Jersey's largest health network from the ground up. A national search for his successor is now underway, with the Board targeting a decision by the end of the first quarter of 2027.
Since HMH's creation a decade ago, the system has grown to 18 hospitals, 41,000 team members and more than 500 patient care locations across New Jersey — nearly triple its size at launch. Under Garrett, the network also opened the Hackensack Meridian School of Medicine, the state's first new private medical school in decades, alongside a new discovery research center.
Seattle – September 21, 2026 -- Sudheer Koneru, CEO and founder of Zenoti, unveiled a new book, Growth Diaries: How the Best Beauty and Wellness Brands Scale from 1 Store to 100+, drawing on interviews with 42 founders, CEOs, and industry leaders across nine countries.
Growth Diaries organizes the operators' experiences into four stages: the first store, the early chain, infrastructure, and institutional scale, providing a stage-by-stage framework for founders scaling service-based businesses. The book argues that beauty, wellness, and fitness brands face distinct scaling challenges compared to software, retail, or restaurant companies, since services are delivered live and an unfilled appointment cannot be recovered as revenue later.
Taipei – September 21, 2026 -- Merry Life Biomedical has advanced TML-6, a Taiwan-developed oral therapy for early Alzheimer's disease, into a global Phase 2 trial spanning 20 clinical sites across Taiwan, Sweden, and the United States, targeting approximately 210 participants.
The study includes nine medical centers in Taiwan, seven sites in Sweden, and four centers in the United States, with Taiwan forming the largest single group of participating sites. The randomized, double-blind, placebo-controlled trial will assign patients to TML-6 100 mg, TML-6 200 mg, or placebo, administered once daily for 52 weeks.